Histone lysine-specific methyltransferases and demethylases in carcino-genesis: New targets for cancer therapy and prevention

Current Cancer Drug Targets

Volumn 13, Issue 5, 2013, Pages 558-579

  Tian, Xuejiao ^a   Zhang, Saiyang ^b   Liu, Hong Min ^b   Zhang, Yan Bing ^b   Blair, Christopher A ^a   Mercola, Dan ^a   Sassone Corsi, Paolo ^a   Zi, Xiaolin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Carcinogenesis; Cell transformation; Gene mutations; Histone lysine specific demethylases; Histone lysine specific methyltransferases; Inhibitors

Indexed keywords

2 CYCLOHEXYL N (1 ISOPROPYL 4 PIPERIDINYL) 6 METHOXY 7 [3 (1 PYRROLIDINYL) PROPOXY] 4 QUINAZOLINAMINE; 2 CYCLOHEXYL N (1 ISOPROPYL 4 PIPERIDINYL) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY] 4 QUINAZOLINAMINE; 2, 2' BIPYRIDINE; 2,4 PYRIDINDICARBOXYLIC ACID; 8 QUINOLINOL; ANDROGEN RECEPTOR; AZ 505; CBB 1007; CHETOCIN; DNA METHYLTRANSFERASE; E 72; EPZ 004777; GLIOTOXIN; GSK 126; GSK 343; GSK J1; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; HISTONE LYSINE DEMETHYLASE; HISTONE LYSINE METHYLTRANSFERASE; HISTONE LYSINE METHYLTRANSFERASE INHIBITOR; METHYLSTAT; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1, 4 DIAZEPIN 1 YL) 6, 7 DIMETHOXY 4 QUINAZOLINAMINE; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; OXALYLGLYCINE; POLYAMINE DERIVATIVE; S ADENOSYLMETHIONINE; SINEFUNGIN A; TRANYLCYPROMINE; UNC 0321; UNC 0646; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER DIAGNOSIS; CANCER PREVENTION; CANCER PROGNOSIS; CANCER THERAPY; CARCINOGENESIS; CELL IMMORTALIZATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE LYSINE METHYLATION; HISTONE METHYLATION; HUMAN; NONHUMAN; REVIEW; RISK ASSESSMENT; TRANSCRIPTION INITIATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA METHYLATION; ENZYME INHIBITORS; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84888090995     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009611313050007     Document Type: Review

References (224)

1. Baylin, S. B.; Jones, P. A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 2011, 11, 726-734.
2. Greer, E. L.; Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat. Rev. Genet. 2012, 13, 343-357.
3. Silverman, L. R.; Demakos, E. P.; Peterson, B. L.; Kornblith, A. B.; et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 2002, 20, 2429-2440.
4. Kantarjian, H.; Issa, J. P.; Rosenfeld, C. S.; Bennett, J. M.; Albitar, M.; DiPersio, J.; Klimek, V.; Slack, J.; de Castro, C.; Ravandi, F.; Helmer, R. 3rd; Shen, L.; Nimer, S. D.; Leavitt, R.; Raza, A.; Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106, 1794-1803.
5. Mann, B. S.; Johnson, J. R.; Cohen, M. H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of; primary cutaneous T-cell lymphoma. Oncologist 2007, 12, 1247-1252.
6. VanderMolen, K. M.; McCulloch, W.; Pearce, C. J.; Oberlies, N. H. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J. Antibiot. (Tokyo) 2011, 64, 525-531.
7. Stresemann, C.; Lyko, F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 2008, 123, 8-13.
8. Choudhary, C.; Kumar, C.; Gnad, F.; Nielsen, M. L; Rehman, M.; Walther, T. C.; Olsen, J.V.; Mann, M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325, 834-840.
9. Kubicek, S.; Gilbert, J. C.; Fomina-Yadlin, D.; Gitlin, A. D.; Yuan, Y.; Wagner, F. F.; Holson, E. B.; Luo, T.; Lewis, T. A.; Taylor, B.; Gupta, S.; Shamji, A. F.; Wagner, B. K.; Clemons, P. A.; Schreiber, S. L. Chromatin-targeting small molecules cause class-specific transcriptional changes in pancreatic endocrine cells. Proc. Natl. Acad. Sci. USA. 2012, 109, 5364-5369.
10. Islam, A. B.; Richter, W. F.; Lopez-Bigas, N.; Benevolenskaya, E. V. Selective targeting of histone methylation. Cell Cycle 2011, 10, 413-24.
11. Popovic, R.; Licht, J. D. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2012, 2, 405-413.
12. Yoshimi, A.; Kurokawa, M. Key roles of histone methyltransferase and demethylase in leukemogenesis. J. Cell Biochem. 2011, 112, 415-424.
13. Hudlebusch, H. R.; Santoni-Rugiu, E.; Simon, R.; Ralfkiær, E.; Rossing, H. H.; Johansen, J. V.; Jørgensen, M.; Sauter, G.; Helin, K. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin. Cancer Res. 2011, 17, 2919-2933.
14. Bernt, K. M.; Zhu, N.; Sinha, A. U.; Vempati, S.; Faber, J.; Krivtsov, A. V.; Feng, Z.; Punt, N.; Daigle, A.; Bullinger, L.; Pollock, R. M.; Richon, V. M.; Kung, A. L.; Armstrong, S. A. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20, 66-78.
15. Méreau, H.; De Rijck, J.; Cermáková, K.; Kutz, A.; Juge, S.; Demeulemeester, J.; Gijsbers, R.; Christ, F.; Debyser, Z.; Schwaller, J. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Leukemia. 2013 [Epub ahead of print].
16. Hormaeche, I.; Licht, J. D. Chromatin modulation by oncogenic transcription factors: new complexity, new therapeutic targets. Cancer Cell. 2007, 11, 475-478.
17. Cock-Rada, A. M.; Medjkane, S.; Janski, N.; Yousfi, N.; Perichon, M.; Chaussepied, M.; Chluba, J.; Langsley, G.; Weitzman, J. B. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012, 72, 810-820.
18. Arita, A.; Shamy, M. Y.; Chervona, Y.; Clancy, H. A.; Sun, H.; Hall, M. N.; Qu Q.; Gamble, M. V.; Costa, M. The effect of exposure to carcinogenic metals on histone tail modifications and gene expression in human subjects. J. Trace Elem. Med. Biol. 2012, 26, 174-178.
19. Spannhoff, A.; Hauser, A. T.; Heinke, R.; Sippl, W.; Jung, M. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. Chem. Med. Chem. 2009, 4, 1568-1582.
20. Arrowsmith, C. H.; Bountra, C.; Fish, P.V.; Lee, K.; Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 2012, 11, 384-400.
21. Guenther, M. G.; Levine, S. S.; Boyer, L. A.; Jaenisch, R.; Young, R. A. A chromatin landmark and transcription initiation at most promoters in human cells. Cell 2007, 130, 77-88.
22. Black, J. C.; Whetstine, J. R. Tipping the lysine methylation balance in disease. Biopolymers 2013, 99, 127-135.
23. Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstine, J. R.; Cole, P. A.; Casero, R. A.; Shi, Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119, 941-953.
24. Heightman, T. D. Chemical biology of lysine demethylases. Curr. Chem. Genomics 2011, 5 (Suppl 1), 62-71.
25. Kaneda, A.; Matsusaka, K.; Aburatani, H.; Fukayama, M. Epstein-barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 2012, 72, 3445-3450.
26. Anderton, J. A.; Bose, S.; Vockerodt, M, Vrzalikova, K.; Wei, W.; Kuo, M.; Helin, K.; Christensen, J.; Rowe, M.; Murray, P. G.; Woodman, C.B. The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma. Oncogene 2011, 30, 2037-2043.
27. Hyland, P. L.; Mcdade, S. S.; Mccloskey, R., Dickson, G. J.; Arthur, K.; McCance, D. J.; Patel, D. Evidence for alteration of EZH2, BMI1, and KDM6A and epigenetic reprogramming in human papillomavirus type 16 E6/E7-expressing keratinocytes. J. Virol. 2011, 85, 10999-101006.
28. Luo, X. G.; Xi, T.; Guo, S.; Liu, Z. P.; Wang, N.; Jiang, Y.; Zhang, T. C. Effects of SMYD3 overexpression on transformation, serum dependence, and apoptosis sensitivity in NIH3T3 cells. IUBMB Life 2009, 61, 679-684.
29. Bradley, C.; Van der meer, R.; Roodi, N, Yan, H.; Chandrasekharan, M. B.; Sun, Z. W.; Mernaugh, R. L.; Parl, F. F. Carcinogen-induced histone alteration in normal human mammary epithelial cells. Carcinogenesis 2007, 28, 2184-2192.
30. Li, Q.; Ke, Q.; Costa M. Alterations of histone modifications by cobalt compounds. Carcinogenesis 2009, 30, 1243-1251.
31. Chervona, Y.; Arita, A.; Costa, M. Carcinogenic metals and the epigenome: understanding the effect of nickel, arsenic, and chromium. Metallomics 2012, 4, 619-627.
32. Zhou, X.; Sun, H.; Ellen, T. P.; Chen, H.; Costa M. Arsenite alters global histone H3 methylation. Carcinogenesis 2008, 29, 1831-1836.
33. Chen, H.; Kluz, T.; Zhang, R.; Costa M. Hypoxia and nickel inhibit histone demethylase JMJD1A and repress Spry2 expression in human bronchial epithelial BEAS-2B cells. Carcinogenesis 2010, 31, 2136-2144.
34. Chen, H.; Ke, Q.; Kluz, T.; Yan, Y.; Costa M. Nickel ions increase histone H3 lysine 9 dimethylation and induce transgene silencing. Mol. Cell Biol. 2006, 26, 3728-3737.
35. Atkinson, S. P.; Hoare, S. F.; Glasspool, R. M.; Keith, W. N. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res. 2005, 65, 7585-7590.
36. Liu, C.; Fang, X.; Ge, Z. Jalink, M.; Kyo, S.; Björkholm, M.; Gruber, A.; Sjöberg, J.; Xu D. The telomerase reverse transcriptase (hTERT) gene is a direct target of the histone methyltransferase SMYD3. Cancer Res. 2007, 67, 2626-31.
37. Hamamoto, R.; Furukawa, Y.; Morita M. Iimura, Y.; Silva, F. P.; Li, M.; Yagyu, R.; Nakamura, Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6, 731-740.
38. Zhu, Q.; Liu, C.; Ge, Z.; Fang, X.; Zhang, X.; Strååt, K.; Björkholm, M.; Xu, D. Lysine-specific demethylase 1 (LSD1) is required for the transcriptional repression of the telomerase reverse transcriptase (hTERT) gene. PLoS ONE. 2008, 3, e1446.
39. Pfau, R.; Tzatsos, A.; Kampranis, S. C.; Serebrennikova, O. B.; Bear, S. E.; Tsichlis, P. N. Members of a family of JmjC domain-containing oncoproteins immortalize embryonic fibroblasts via a JmjC domain-dependent process. Proc. Natl. Acad. Sci. USA 2008, 105, 1907-1912.
40. Tzatsos, A.; Pfau, R.; Kampranis, S. C.; Tsichlis, P. N. Ndy1/KDM2B immortalizes mouse embryonic fibroblasts by repressing the Ink4a/Arf locus. Proc. Natl. Acad. Sci. USA 2009, 106, 2641-2646.
41. Okada, Y.; Feng, Q.; Lin, Y., Jiang, Q.; Li, Y.; Coffield, V. M.; Su, L.; Xu, G.; Zhang, Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121, 167-178.
42. Chang, M. J.; Wu, H.; Achille, N. J.; Reisenauer, M. R.; Chou, C. W.; Zeleznik-Le, N. J.; Hemenway, C. S.; Zhang, W. Histone H3 lysine 79 methyltransferase Dot1 is required for immortalization by MLL oncogenes. Cancer Res. 2010, 70, 10234-42.
43. Bernt, K. M.; Armstrong, S. A. A role for DOT1L in MLL-rearranged leukemias. Epigenomics 2011, 3, 667-670.
44. Daigle, S. R.; Olhava, E. J.; Therkelsen, C. A. Majer, C. R.; Sneeringer, C. J.; Song, J.; Johnston, L. D.; Scott, M. P.; Smith, J. J.; Xiao, Y.; Jin, L.; Kuntz, K. W.; Chesworth, R.; Moyer, M. P.; Bernt, K. M.; Tseng, J. C.; Kung, A. L.; Armstrong, S. A.; Copeland, R. A.; Richon, V. M.; Pollock, R. M. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20, 53-65.
45. Weinstein, I. B.; Joe, A. K. Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin. Pract. Oncol. 2006, 3, 448-457.
46. Kuo, A. J.; Cheung, P.; Chen, K.; Zee, B. M.; Kioi, M.; Lauring, J.; Xi, Y.; Park, B. H.; Shi, X.; Garcia, B. A.; Li, W.; Gozani, O. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell. 2011, 44, 609-620.
47. Wang, G. G.; Cai, L.; Pasillas, M. P.; Kamps, M. P. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat. Cell Biol. 2007, 9, 804-812.
48. Spensberger, D., Delwel, R. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett. 2008, 582, 2761-2767.
49. Mulligan, P.; Westbrook, T. F.; Ottinger, M., Pavlova, N.; Chang, B.;, Macia, E;, Shi, Y. J.; Barretina, J; Liu, J.; Howley, P. M.; Elledge, S. J.; Shi, Y. CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. Mol. Cell. 2008, 32, 718-726.
50. Herrera-merchan, A.; Arranz, L.; Ligos, J. M.; De Molina, A.; Dominguez, O.; Gonzalez, S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat. Commun. 2012, 3, 623.
51. Karanikolas, B. D.; Figueiredo, M. L.; Wu, L. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol. Cancer Res. 2009, 7, 1456-1465.
52. He, J.; Nguyen, A. T.; Zhang, Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 2011, 7, 3869-3880.
53. Yang, Z. Q.; Liu, G.; Bollig-fischer, A.; Giroux, C. N.; Ethier, S. P. Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res. 2010, 70, 8487-8497.
54. Boffa, L. C.; Bolognesi, C. Methylating agents: their target amino acids in nuclear proteins. Carcinogenesis. 1985, 6, 1399-13401.
55. Pinsky, S. D.; Lee, K. E.; Woolley, P. V. 3rd. Uptake and binding of 1-methyl-1-nitrosourea (MNU) and 1-methyl-3-nitro-1-nitrosoguanidine (MNNG) by the isolated guinea pig pancreas. Carcinogenesis 1980, 1, 567-575.
56. Starlard-davenport, A.; Tryndyak, V. P.; James, S. R. Karpf, A. R.; Latendresse, J. R.; Beland, F. A.; Pogribny, I. P. Mechanisms of epigenetic silencing of the Rassf1a gene during estrogen-induced breast carcinogenesis in ACI rats. Carcinogenesis 2010, 31, 376-381.
57. Tryndyak, V. P.; Muskhelishvili, L.; Kovalchuk, O. Rodriguez-Juarez, R.; Montgomery, B.; Churchwell, M. I.; Ross, S. A.; Beland, F. A.; Pogribny, I. P. Effect of long-term tamoxifen exposure on genotoxic and epigenetic changes in rat liver: implications for tamoxifen-induced hepatocarcinogenesis. Carcinogenesis 2006, 27, 1713-1720.
58. Kovalchuk, O.; Tryndyak, V. P.; Montgomery B.; Boyko, A.; Kutanzi, K.; Zemp, F.; Warbritton, A. R.; Latendresse, J. R.; Kovalchuk, I.; Beland, F. A.; Pogribny, I. P. Estrogen-induced rat breast carcinogenesis is characterized by alterations in DNA methylation, histone modifications and aberrant microRNA expression. Cell Cycle 2007, 6, 2010-2018.
59. Pogribny, I. P.; Muskhelishvili, L.; Tryndyak, V. P.; Beland, F. A. The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene. Mutat. Res. 2011, 722, 106-113.
60. Bagnyukova, T. V.; Tryndyak, V. P.; Montgomery, B.; Churchwell, M. I.; Karpf, A. R.; James, S. R.; Muskhelishvili, L.; Beland, F. A.; Pogribny, I. P. Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene. Carcinogenesis 2008, 29, 638-646.
61. Pogribny, I. P.; Ross, S. A.; Tryndyak, V. P.; Pogribna, M.; Poirier, L. A.; Karpinets, T. V. Histone H3 lysine 9 and H4 lysine 20 trimethylation and the expression of Suv4-20h2 and Suv-39h1 histone methyltransferases in hepatocarcinogenesis induced by methyl deficiency in rats. Carcinogenesis 2006, 27, 1180-1186.
62. Nguyen, C. T.; Weisenberger, D. J.; Velicescu, M.; Gonzales, F. A.; Lin, J. C.; Liang, G; Jones, P. A. Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. Cancer Res. 2002, 62, 6456-6461.
63. Wozniak, R. J.; Klimecki, W. T.; Lau, S. S.; Feinstein, Y., Futscher, B. W. 5-Aza-2'-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 2007, 26, 77-90.
64. Hashimoto, H.; Vertino, P. M.; Cheng, X. Molecular coupling of DNA methylation and histone methylation. Epigenomics 2010, 2, 657-669.
65. Cedar, H.; Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10, 295-304.
66. Wong, C. M.; Wong, C. C.; Ng, Y. L.; Au, S. L.; Ko, F. C.; Ng, I. O. Transcriptional repressive H3K9 and H3K27 methylations contribute to DNMT1-mediated DNA methylation recovery. PLoS ONE. 2011, 6, e16702.
67. Wang, J.; Hevi, S.; Kurash, J. K.; Lei, H.; Gay, F.; Bajko, J.; Su, H.; Sun, W.; Chang, H.; Xu, G.; Gaudet, F.; Li, E.; Chen, T. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat. Genet. 2009, 41, 125-129.
68. Bernstein, B. E.; Mikkelsen, T. S.; Xie, X. Kamal, M.; Huebert, D. J.; Cuff, J.; Fry, B.; Meissner, A.; Wernig, M.; Plath, K.; Jaenisch, R.; Wagschal, A.; Feil, R.; Schreiber, S. L.; Lander, E. S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125, 315-326.
69. Ohm, J. E.; Mcgarvey, K. M.; Yu, X.; Cheng, L.; Schuebel, K. E.; Cope, L.; Mohammad, H. P.; Chen, W.; Daniel, V. C.; Yu, W.; Berman, D. M.; Jenuwein, T.; Pruitt, K.; Sharkis, S. J.; Watkins, D. N.; Herman, J. G.; Baylin, S. B. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 2007, 39, 237-242.
70. Schlesinger, Y.; Straussman, R.; Keshet, I.; Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, Bergman Y, Simon I, Cedar H. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 2007, 39, 232-236.
71. Widschwendter, M.; Fiegl, H.; Egle, D. Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I, Laird PW. Epigenetic stem cell signature in cancer. Nat. Genet. 2007, 39, 157-158.
72. Ohm, J. E.; Baylin, S. B. Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle 2007, 6, 1040-1043.
73. Vallot, C.; Stransky, N.; Bernard-pierrot I.; Hérault, A.; Zucman-Rossi, J.; Chapeaublanc, E.; Vordos, D.; Laplanche, A.; Benhamou, S.; Lebret, T.; Southgate, J.; Allory, Y.; Radvanyi, F. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J. Natl. Cancer Inst. 2011, 103, 47-60.
74. Lohr, J. G.; Stojanov, P.; Lawrence, M. S.; Auclair, D.; Chapuy, B.; Sougnez, C.; Cruz-Gordillo, P.; Knoechel, B.; Asmann, Y. W.; Slager, S. L.; Novak, A. J.; Dogan, A.; Ansell, S. M.; Link, B. K.; Zou, L.; Gould, J.; Saksena, G.; Stransky, N.; Rangel-Escareño, C.; Fernandez-Lopez, J. C.; Hidalgo-Miranda, A.; Melendez-Zajgla, J.; Hernández-Lemus, E.; Schwarz-Cruzy Celis, A.; Imaz-Rosshandler, I.; Ojesina, A. I.; Jung, J.; Pedamallu, C. S.; Lander, E. S.; Habermann, T. M.; Cerhan, J. R.; Shipp, M. A.; Getz, G.; Golub, T. R. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci USA 2012, 109, 3879-3884.
75. Saramäki, O. R.; Tammela, T. L.; Martikainen, P. M.; Vessella, R. L.; Visakorpi, T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006, 45, 639-645.
76. Yamada, A.; Fujii, S.; Daiko, H.; Nishimura, M.; Chiba, T.; Ochiai, A. Aberrant expression of EZH2 is associated with a poor outcome and P53 alteration in squamous cell carcinoma of the esophagus. Int. J. Oncol. 2011, 38, 345-353.
77. He, L. R.; Liu, M. Z.; Li, B. K.; Jia, W. H.; Zhang, Y.; Liao, Y. J.; Chen, Y. C.; Zhang, L. J.; Guan, X. Y.; Zeng, Y. X.; Kung, H. F.; Xie, D. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int. J. Cancer 2010, 127, 138-147.
78. Jankowska, A. M.; Makishima, H.; Tiu, R. V.; Szpurka, H.; Huang, Y.; Traina, F.; Visconte, V.; Sugimoto, Y.; Prince, C.; O'Keefe, C.; Hsi, E. D.; List, A.; Sekeres, M. A.; Rao, A.; McDevitt, M. A.; Maciejewski, J. P. Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 2011, 118, 3932-3941.
79. Morin, R. D.; Johnson, N. A.; Severson, T. M.; Mungall, A. J.; An, J.; Goya, R.; Paul, J. E.; Boyle, M.; Woolcock, B. W.; Kuchenbauer, F.; Yap, D.; Humphries, R. K.; Griffith, O. L.; Shah, S.; Zhu, H.; Kimbara, M.; Shashkin, P.; Charlot, J. F.; Tcherpakov, M.; Corbett, R.; Tam, A.; Varhol, R.; Smailus, D.; Moksa, M.; Zhao, Y.; Delaney, A.; Qian, H.; Birol, I.; Schein, J.; Moore, R.; Holt, R.; Horsman, D. E.; Connors, J. M.; Jones, S.; Aparicio, S.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 2010, 42, 181-185.
80. Yap, D. B.; Chu, J.; Berg, T.; Schapira, M.; Cheng, S. W.; Moradian, A.; Morin, R. D.; Mungall, A. J.; Meissner, B.; Boyle, M.; Marquez, V. E.; Marra, M. A.; Gascoyne, R. D.; Humphries, R. K.; Arrowsmith, C. H.; Morin, G. B.; Aparicio, S. A. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 2011, 117, 2451-2459.
81. Bödör, C.; O'riain, C.; Wrench, D. Matthews J, Iyengar S, Tayyib H, Calaminici M, Clear A, Iqbal S, Quentmeier H, Drexler HG, Montoto S, Lister AT, Gribben JG, Matolcsy A, Fitzgibbon J. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011, 25, 726-729.
82. Mccabe, M. T.; Graves, A. P.; Ganji, G.; Diaz, E.; Halsey, W. S.; Jiang, Y.; Smitheman, K. N.; Ott, H. M.; Pappalardi, M. B.; Allen, K. E.; Chen, S. B.; Della, Pietra A. 3rd; Dul, E.; Hughes, A. M.; Gilbert, S. A.; Thrall, S. H.; Tummino, P. J.; Kruger, R. G.; Brandt, M.; Schwartz, B.; Creasy, C. L. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl. Acad. Sci. USA 2012, 109, 2989-2994.
83. Ryan, R. J.; Nitta, M.; Borger, D.; Zukerberg, L. R.; Ferry, J. A.; Harris, N. L.; Iafrate, A. J.; Bernstein, B. E.; Sohani, A. R.; Le, L. P. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE 2011, 6, e28585.
84. Salido, M.; Martinez-avilés, L.; Ademà, V.; Ferrer, A.; Espinet, B.; Garcia, M.; Salar, A.; Besses, C.; Florensa, L.; Serrano, S.; Bellosillo, B.; Solé F. Absence of mutations of the histone methyltransferase gene EZH2 in splenic b-cell marginal zone lymphoma. Leuk. Res. 2011, 35, e23-e24.
85. Sneeringer, C. J.; Scott, M. P.; Kuntz, K. W.; Knutson, S. K.; Pollock, R. M.; Richon, V. M; Copeland, R. A. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl. Acad. Sci. USA 2010, 107, 20980-20985.
86. Abdel-wahab, O.; Pardanani, A.; Patel, J.; Wadleigh, M.; Lasho, T.; Heguy, A.; Beran, M.; Gilliland, D. G.; Levine, R. L.; Tefferi, A. Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 2011, 25, 1200-1202.
87. Nikoloski, G.; Langemeijer, S. M.; Kuiper, R. P.; Knops, R.; Massop, M.; Tönnissen, E. R.; van der Heijden, A.; Scheele, T. N.; Vandenberghe, P.; de Witte, T.; van der Reijden, B. A.; Jansen, J. H. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 2010, 42, 665-677.
88. Makishima, H.; Jankowska, A. M.; Tiu, R. V.; Szpurka, H.; Sugimoto, Y.; Hu, Z.; Saunthararajah, Y.; Guinta, K.; Keddache, M. A.; Putnam, P.; Sekeres, M. A.; Moliterno, A. R.; List, A. F.; McDevitt, M. A.; Maciejewski, J. P. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia 2010, 24, 1799-1804.
89. Park, S. W.; Chung, N. G.; Eom, H. S.; Yoo, N. J.; Lee, S. H. Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias. Leuk. Res. 2011, 35, e6-e7.
90. Ernst, T.; Chase, A. J.; Score, J.; Hidalgo-Curtis, C. E.; Bryant, C.; Jones, A. V.; Waghorn, K.; Zoi, K.; Ross, F. M.; Reiter, A.; Hochhaus, A.; Drexler, H. G.; Duncombe, A.; Cervantes, F.; Oscier, D.; Boultwood, J.; Grand, F. H.; Cross, N. C. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat. Genet. 2010, 42, 722-736.
91. van Haaften, G.; Dalgliesh, G. L.; Davies, H.; Chen, L.; Bignell, G.; Greenman, C.; Edkins, S.; Hardy, C.; O'Meara, S.; Teague, J.; Butler, A.; Hinton, J.; Latimer, C.; Andrews, J.; Barthorpe, S.; Beare, D.; Buck, G.; Campbell, P. J.; Cole, J.; Forbes, S.; Jia, M; Jones, D.; Kok, C. Y.; Leroy, C.; Lin, M. L.; McBride, D. J.; Maddison, M.; Maquire, S.; McLay, K.; Menzies, A.; Mironenko, T.; Mulderrig, L.; Mudie, L.; Pleasance, E.; Shepherd, R.; Smith, R.; Stebbings, L.; Stephens, P.; Tang, G.; Tarpey, P. S.; Turner, R.; Turrell, K.; Varian, J.; West, S.; Widaa, S.; Wray, P.; Collins, V. P.; Ichimura, K.; Law, S.; Wong, J.; Yuen, S. T.; Leung, S.Y.; Tonon, G.; DePinho, R. A.; Tai, Y. T.; Anderson, K. C.; Kahnoski, R. J.; Massie, A.; Khoo, S. K.; Teh, B. T.; Stratton, M. R.; Futreal, P. A. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 2009, 41, 521-533.
92. Mar, B. G.; Bullinger, L.; Basu, E.; Schlis, K.; Silverman, L. B.; Döhner, K.; Armstrong, S. A. Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia. Leukemia 2012, 26, 1881-1893.
93. Gui, Y.; Guo, G.; Huang, Y.; Hu, X.; Tang, A.; Gao, S.; Wu, R.; Chen, C.; Li, X.; Zhou, L.; He, M.; Li, Z.; Sun, X.; Jia, W.; Chen, J.; Yang, S.; Zhou, F.; Zhao, X.; Wan, S.; Ye, R.; Liang, C.; Liu, Z.; Huang, P.; Liu, C.; Jiang, H.; Wang, Y.; Zheng, H.; Sun, L.; Liu, X.; Jiang, Z.; Feng, D.; Chen, J.; Wu, S.; Zou, J.; Zhang, Z.; Yang, R.; Zhao, J.; Xu, C.; Yin, W.; Guan, Z.; Ye, J.; Zhang, H.; Li, J.; Kristiansen, K.; Nickerson, M. L.; Theodorescu, D.; Li, Y.; Zhang, X.; Li, S.; Wang, J.; Yang, H.; Wang, J.; Cai, Z. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 2011, 43, 875-888.
94. Dalgliesh, G. L.; Furge, K.; Greenman, C.; Chen, L.; Bignell, G.; Butler, A.; Davies, H.; Edkins, S.; Hardy, C.; Latimer, C.; Teague, J.; Andrews, J.; Barthorpe, S.; Beare, D.; Buck, G.; Campbell, P. J.; Forbes, S.; Jia, M.; Jones, D.; Knott, H.; Kok, C. Y.; Lau, K. W.; Leroy, C.; Lin, M. L.; McBride, D. J.; Maddison, M.; Maguire, S.; McLay, K.; Menzies, A.; Mironenko, T.; Mulderrig, L.; Mudie, L.; O'Meara, S.; Pleasance, E.; Rajasingham, A.; Shepherd, R.; Smith, R.; Stebbings, L.; Stephens, P.; Tang, G.; Tarpey, P. S.; Turrell, K.; Dykema, K. J.; Khoo, S. K.; Petillo, D.; Wondergem, B.; Anema, J.; Kahnoski, R. J.; Teh, B. T.; Stratton, M. R.; Futreal, P. A. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010, 463, 360-373.
95. Grasso, C. S.; Wu, Y. M.; Robinson, D. R.; Cao, X.; Dhanasekaran, S. M.; Khan, A. P.; Quist, M. J.; Jing, X.; Lonigro, R. J.; Brenner, J. C.; Asangani, I. A.; Ateeq, B.; Chun, S. Y.; Siddiqui, J.; Sam, L.; Anstett, M.; Mehra, R.; Prensner, J. R.; Palanisamy, N.; Ryslik, G. A.; Vandin, F.; Raphael, B. J.; Kunju, L. P.; Rhodes, D. R.; Pienta, K. J.; Chinnaiyan, A. M.; Tomlins, S. A. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487, 239-243.
96. Ansari, K. I.; Mandal, S. S. Mixed lineage leukemia: roles in gene expression, hormone signaling and mRNA processing. FEBS J. 2010, 277, 1790-1804.
97. Morin, R. D.; Mendez-lago, M.; Mungall, A. J.; Goya, R.; Mungall, K. L.; Corbett, R. D.; Johnson, N. A.; Severson, T. M.; Chiu, R.; Field, M.; Jackman, S.; Krzywinski, M.; Scott, D. W.; Trinh, D. L.; Tamura-Wells, J.; Li, S.; Firme, M. R.; Rogic, S.; Griffith, M.; Chan, S.; Yakovenko, O.; Meyer, I. M.; Zhao, E. Y.; Smailus, D.; Moksa, M.; Chittaranjan, S.; Rimsza, L.; Brooks-Wilson, A.; Spinelli, J. J.; Ben-Neriah, S.; Meissner, B.; Woolcock, B.; Boyle, M.; McDonald, H.; Tam, A.; Zhao, Y.; Delaney, A.; Zeng, T.; Tse, K.; Butterfield, Y.; Birol, I.; Holt, R.; Schein, J.; Horsman, D. E.; Moore, R.; Jones, S. J.; Connors, J. M.; Hirst, M.; Gascoyne, R. D.; Marra, M. A. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476, 298-303.
98. Chapman, M. A.; Lawrence, M. S.; Keats, J. J.; Cibulskis, K.; Sougnez, C.; Schinzel, A. C.; Harview, C. L.; Brunet, J. P.; Ahmann, G. J.; Adli, M.; Anderson, K. C.; Ardlie, K. G.; Auclair, D.; Baker, A.; Bergsagel, P. L.; Bernstein, B. E.; Drier, Y.; Fonseca, R.; Gabriel, S. B.; Hofmeister, C. C.; Jagannath, S.; Jakubowiak, A. J.; Krishnan, A.; Levy, J.; Liefeld, T.; Lonial, S.; Mahan, S.; Mfuko, B.; Monti, S.; Perkins, L. M.; Onofrio, R.; Pugh, T. J.; Rajkumar, S. V.; Ramos, A. H.; Siegel, D. S.; Sivachenko, A.; Stewart, A. K.; Trudel, S.; Vij, R.; Voet, D.; Winckler, W.; Zimmerman, T.; Carpten, J.; Trent, J.; Hahn, W. C.; Garraway, L. A.; Meyerson, M.; Lander, E. S.; Getz, G.; Golub, T. R. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471, 467-472.
99. Pleasance, E. D.; Stephens, P. J.; O'meara, S.; McBride, D. J.; Meynert, A.; Jones, D.; Lin, M. L.; Beare, D.; Lau, K. W.; Greenman, C.; Varela, I.; Nik-Zainal, S.; Davies, H. R.; Ordoñez, G. R.; Mudie, L. J.; Latimer, C.; Edkins, S.; Stebbings, L.; Chen, L.; Jia, M.; Leroy, C.; Marshall, J.; Menzies, A.; Butler, A.; Teague, J. W.; Mangion, J.; Sun, Y. A.; McLaughlin, S. F.; Peckham, H. E.; Tsung, E. F.; Costa, G. L.; Lee, C. C.; Minna, J. D.; Gazdar, A.; Birney, E.; Rhodes, M. D.; McKernan, K. J.; Stratton, M. R.; Futreal, P. A.; Campbell, P. J. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010, 463, 184-190.
100. Wang, X. X.; Fu, L.; Li, X.; Wu, X.; Zhu, Z.; Fu, L.; Dong, J. T. Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol. Oncol. Res. 2011, 17, 429-433.
101. Watanabe, Y.; Castoro, R. J.; Kim, H. S.; North, B.; Oikawa, R.; Hiraishi, T.; Ahmed, S. S.; Chung, W.; Cho, M. Y.; Toyota, M.; Itoh, F.; Estecio, M. R.; Shen, L.; Jelinek, J.; Issa, J. P. Frequent alteration of MLL3 frameshift mutations in microsatellite deficient colorectal cancer. PLoS ONE 2011, 6, e23320.
102. Lee, J.; Kim, D. H.; Lee, S.; Yang, Q. H.; Lee, D. K.; Lee, S. K.; Roeder, R. G.; Lee, J. W. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proc. Natl. Acad. Sci USA 2009, 106, 8513-8518.
103. Zhang, J.; Ding, L.; Holmfeldt, L.; Wu, G.; Heatley, S. L.; Payne-Turner, D.; Easton, J.; Chen, X.; Wang, J.; Rusch, M.; Lu, C.; Chen, S. C.; Wei, L.; Collins-Underwood, J. R.; Ma, J.; Roberts, K. G.; Pounds, S. B.; Ulyanov, A.; Becksfort, J.; Gupta, P.; Huether, R.; Kriwacki, R. W.; Parker, M.; McGoldrick, D. J.; Zhao, D.; Alford, D.; Espy, S.; Bobba, K. C.; Song, G.; Pei, D.; Cheng, C.; Roberts, S.; Barbato, M. I.; Campana, D.; Coustan-Smith, E.; Shurtleff, S. A.; Raimondi, S. C.; Kleppe, M.; Cools, J.; Shimano, K. A.; Hermiston, M. L.; Doulatov, S.; Eppert, K.; Laurenti, E.; Notta, F.; Dick, J. E.; Basso, G.; Hunger, S. P.; Loh, M. L.; Devidas, M.; Wood, B.; Winter, S.; Dunsmore, K. P.; Fulton, R. S.; Fulton, L. L.; Hong, X.; Harris, C. C.; Dooling, D. J.; Ochoa, K.; Johnson, K. J.; Obenauer, J. C.; Evans, W. E.; Pui, C. H.; Naeve, C. W.; Ley, T. J.; Mardis, E. R; Wilson, R. K.; Downing, J. R.; Mullighan, C. G. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012, 481, 157-163.
104. Gerlinger, M.; Rowan, A. J.; Horswell, S. Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; Begum, S.; McDonald, N. Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; Santos, C. R.; Nohadani, M.; Eklund, A. C.; Spencer-Dene, B.; Clark, G.; Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P. A.; Swanton, C. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 2012, 366, 883-892.
105. MacKinnon, R. N.; Kannourakis, G.; Wall, M.; Campbell, L. J. A cryptic deletion in 5q31.2 provides further evidence for a minimally deleted region in myelodysplastic syndromes. Cancer Genet. 2011, 204, 187-194.
106. Lohr, J. G.; Stojanov, P.; Lawrence, M. S.; Auclair, D.; Chapuy, B.; Sougnez, C.; Cruz-Gordillo, P.; Knoechel, B.; Asmann, Y. W.; Slager, S. L.; Novak, A. J.; Dogan, A.; Ansell, S. M.; Link, B. K.; Zou, L.; Gould, J.; Saksena, G.; Stransky, N.; Rangel-Escareño, C.; Fernandez-Lopez, J. C.; Hidalgo-Miranda, A.; Melendez-Zajgla, J.; Hernández-Lemus, E.; Schwarz-Cruzy Celis, A.; Imaz-Rosshandler, I.; Ojesina, A. I.; Jung, J.; Pedamallu, C. S.; Lander, E. S; Habermann, T. M.; Cerhan, J. R.; Shipp, M. A.; Getz, G.; Golub, T. R. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 2012, 109, 3879-3884.
107. Cross, N. C. Histone modification defects in developmental disorders and cancer. Oncotarget. 2012, 3, 3-4.
108. Hudlebusch, H. R.; Santoni-rugiu, E.; Simon, R.; Ralfkiær, E.; Rossing, H. H.; Johansen, J. V.; Jørgensen, M.; Sauter, G.; Helin, K. The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors. Clin. Cancer Res. 2011, 17, 2919-2933.
109. Jaju, R. J.; Fidler, C.; Haas, O. A.; Strickson, A. J.; Watkins, F.; Clark, K.; Cross, N. C.; Cheng, J. F.; Aplan, P. D.; Kearney, L.; Boultwood, J.; Wainscoat, J. S. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood 2001, 98, 1264-1277.
110. Krivtsov, A. V., Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7, 823-833.
111. Yu, B. D.; Hess, J. L.; Horning, S. E.; Brown, G. A.; Korsmeyer, S. J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995, 378, 505-508.
112. Behm, F. G.; Raimondi, S.C.; Frestedt, J. L.; Liu, Q.; Crist, W. M.; Downing, J. R.; Rivera, G. K.; Kersey, J. H.; Pui, C. H. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood 1996, 87, 2870-2877.
113. Huo, H.; Magro, P. G.; Pietsch, E. C; Patel, B. B.; Scotto, K. W. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 2010, 70, 8726-35.
114. Angrand, P. O.; Apiou, F.; Stewart, A. F.; Dutrillaux, B.; Losson, R.; Chambon, P. NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 2001, 74, 79-88.
115. Kassambara, A.; Klein, B.; Moreaux, J. MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem. Biophys. Res. Commun. 2009, 379, 840-855.
116. Hudlebusch, H. R.; Skotte, J.; Santoni-rugiu, E.; Zimling, Z. G.; Lees, M. J.; Simon, R.; Sauter, G; Rota, R.; De Ioris, M. A.; Quarto, M.; Johansen, J. V.; Jørgensen, M.; Rechnitzer, C; Maroun, L. L.; Schrøder, H.; Petersen, B. L.; Helin, K. MMSET is highly expressed and associated with aggressiveness in neuroblastoma. Cancer Res. 2011, 71, 4226-4235.
117. Zatkova, A.; Merk, S.; Wendehack, M.; Bilban, M.; Muzik, E. M.; Muradyan, A.; Haferlach, C; Haferlach, T.; Wimmer, K.; Fonatsch, C; Ullmann, R. AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes. Genes Chromosomes Cancer 2009, 48, 510-520.
118. Hamamoto, R.; Furukawa, Y.; Morita, M.; Iimura, Y.; Silva, F. P.; Li, M.; Yagyu, R.; Nakamura, Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat. Cell Biol. 2004, 6, 731-740.
119. Luo, X. G.; Ding, Y.; Zhou, Q. F.; Ye, L.; Wang, S. Z.; Xi, T. SET and MYND domain-containing protein 3 decreases sensitivity to dexamethasone and stimulates cell adhesion and migration in NIH3T3 cells. J. Biosci. Bioeng. 2007, 103, 444-450.
120. Silva, F. P.; Hamamoto, R.; Kunizaki, M.; Tsuge, M.; Nakamura, Y.; Furukawa, Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene 2008, 27, 2686-2692.
121. Brown, M. A.; Sims, R. J.; Gottlieb, P. D.; Tucker, P. W. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Mol. Cancer 2006, 5, 26.
122. Huang, J.; Perez-burgos, L.; Placek, B. J.; Sengupta, R.; Richter, M.; Dorsey, J. A.; Kubicek, S.; Opravil, S.; Jenuwein, T.; Berger, S. L. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006, 444, 629-632.
123. Komatsu, S.; Imoto, I.; Tsuda H.; Kozaki, K. I.; Muramatsu, T.; Shimada, Y.; Aiko, S.; Yoshizumi, Y.; Ichikawa, D.; Otsuji, E.; Inazawa, J. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis 2009, 30, 1139-1146.
124. Peters, A. H.; O'carroll, D.; Scherthan, H.; Mechtler, K.; Sauer, S.; Schöfer, C; Weipoltshammer, K.; Pagani, M.; Lachner, M.; Kohlmaier, A.; Opravil, S.; Doyle, M.; Sibilia, M.; Jenuwein, T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001, 107, 323-337.
125. Ozdag, H.; Teschendorff, A. E.; Ahmed, A. A.; Hyland, S. J.; Blenkiron, C; Bobrow, L.; Veerakumarasivam, A.; Burtt, G.; Subkhankulova, T.; Arends, M. J.; Collins, V. P.; Bowtell, D.; Kouzarides, T.; Brenton, J. D.; Caldas, C. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 2006, 7, 90.
126. Kondo, Y.; Shen, L.; Suzuki, S.; Kurokawa, T.; Masuko, K.; Tanaka, Y.; Kato, H.; Mizuno, Y.; Yokoe, M.; Sugauchi, F.; Hirashima, N.; Orito, E.; Osada, H.; Ueda, R.; Guo, Y.; Chen, X.; Issa, J. P.; Sekido, Y. Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. Hepatol. Res. 2007, 37, 974-983.
127. Ceol, C. J.; Houvras, Y.; Jane-valbuena, J.; Bilodeau, S.; Orlando, D. A.; Battisti, V.; Fritsch, L.; Lin, W. M.; Hollmann, T. J.; Ferré, F.; Bourque, C; Burke, C. J.; Turner, L.; Uong, A.; Johnson, L. A.; Beroukhim, R.; Mermel, C. H.; Loda, M.; Ait-Si-Ali, S.; Garraway, L. A.; Young, R. A.; Zon, L. I. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature 2011, 471, 513-517.
128. Takawa, M.; Masuda, K.; Kunizaki, M.; Daigo, Y.; Takagi, K.; Iwai, Y.; Cho, H. S.; Toyokawa, G.; Yamane, Y.; Maejima, K.; Field, H. I.; Kobayashi, T.; Akasu, T.; Sugiyama, M.; Tsuchiya, E.; Atomi, Y.; Ponder, B. A.; Nakamura, Y.; Hamamoto, R. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 2011, 102, 1298-1305.
129. Bryant, R. J.; Cross, N. A.; Eaton, C. L.; Hamdy, F. C.; Cunliffe, V. T. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007, 67, 547-556.
130. Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419, 624-629.
131. Kauffman, E. C.; Robinson, B. D.; Downes, M. J.; Powell, L. G.; Lee, M. M; Scherr, D. S.; Gudas, L. J.; Mongan, N. P. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 2011, 50, 931-944.
132. Hayami, S.; Kelly, J. D.; Cho, H. S.; Yoshimatsu M, Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, Nakamura Y, Hamamoto R. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer. 2011, 128, 574-586.
133. Kahl, P.; Gullotti, L.; Heukamp, L. C.; Wolf, S.; Friedrichs, N.; Vorreuther, R.; Solleder, G.; Bastian, P. J.; Ellinger, J.; Metzger, E.; Schüle, R.; Buettner, R. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006, 66, 11341-11347.
134. Lim, S.; Janzer, A.; Becker, A.; Zimmer, A.; Schüle, R.; Buettner, R.; Kirfel, J. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010, 31, 512-20.
135. Cloos, P. A.; Christensen, J.; Agger, K.; Maiolica, A.; Rappsilber, J.; Antal, T.; Hansen, K. H.; Helin, K. The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature 2006, 442, 307-311.
136. Ehrbrecht, A.; Müller, U.; Wolter, M.; Hoischen, A.; Koch, A.; Radlwimmer, B.; Actor, B.; Mincheva, A.; Pietsch, T.; Lichter, P.; Reifenberger, G.; Weber, R. G. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 2006, 208, 554-563.
137. Italiano, A.; Attias, R.; Aurias, A.; Pérot, G.; Burel-Vandenbos, F.; Otto, J.; Venissac, N.; Pedeutour, F. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet. Cytogenet. 2006, 167, 122-130.
138. Vinatzer, U.; Gollinger, M.; Müllauer, L.; Raderer, M.; Chott, A.; Streubel, B. Mucosa-associated lymphoid tissue lymphoma: novel translocations including rearrangements of ODZ2, JMJD2C, and CNN3. Clin. Cancer Res. 2008, 14, 6426-6431.
139. Yang, Z. Q.; Imoto, I.; Fukuda, Y.; Pimkhaokham, A.; Shimada, Y.; Imamura, M.; Sugano, S.; Nakamura, Y.; Inazawa, J. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res. 2000, 60, 4735-4739.
140. Ishimura, A.; Terashima, M.; Kimura, H.; Akagi, K.; Suzuki, Y.; Sugano, S.; Suzuki, T. Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene. Biochem Biophys Res Commun. 2009, 389, 366-371.
141. Wissmann, M.; Yin, N.; Müller, J. M.; Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Günther T, Buettner R, Metzger E, Schüle R. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat. Cell Biol. 2007, 9, 347-353.
142. Chi, P.; Allis, C. D.; Wang, G. G. Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10, 457-469.
143. Blair, L. P.; Cao, J.; Zou, M. R.; Sayegh, J.; Yan, Q. Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Cancers (Basel) 2011, 3, 1383-1404.
144. Sharma, S. V.; Lee, D. Y.; Li, B.; Quinlan, M. P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M. A.; Wong, K. K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141, 69-80.
145. Lu, P. J.; Sundquist, K.; Baeckstrom, D.; Poulsom, R.; Hanby, A.; Meier-Ewert, S.; Jones, T.; Mitchell, M.; Pitha-Rowe, P.; Freemont, P.; Taylor-Papadimitriou, J. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J. Biol. Chem. 1999, 274, 15633-15645.
146. Xiang, Y.; Zhu, Z.; Han, G.; Ye, X.; Xu, B.; Peng, Z.; Ma, Y.; Yu, Y.; Lin, H.; Chen, A. P.; Chen, C. D. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 19226-19231.
147. Smith, J. A.; White, E. A.; Sowa, M. E.; Powell, M. L.; Ottinger, M.; Harper, J. W.; Howley, P. M. Genome-wide siRNA screen identifies SMCX, EP400, and Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc. Natl. Acad. Sci. USA 2010, 107, 3752-3757.
148. Xiang, Y.; Zhu, Z.; Han, G.; Lin, H.; Xu, L.; Chen, C. D. JMJD3 is a histone H3K27 demethylase. Cell Res. 2007, 17, 850-857.
149. Frescas, D.; Guardavaccaro, D.; Bassermann, F.; Koyama-nasu, R.; Pagano, M. JHDM1B/FBXL10 is a nucleolar protein that represses transcription of ribosomal RNA genes. Nature 2007, 450, 309-313.
150. Agger, K.; Cloos, P. A.; Christensen, J.; Maiolica, A.; Rappsilber, J.; Antal, T.; Hansen, K. H.; Helin, K. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 2007, 449, 731-7444.
151. Hong, S.; Cho, Y. W.; Yu, L. R.; Yu, H.; Veenstra, T. D.; Ge, K. Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases. Proc. Natl. Acad. Sci. USA 2007, 104, 18439-18444.
152. Tsai, M. C.; Wang, J. K.; Chang, H. Y. Tumor suppression by the histone demethylase UTX. Cell Cycle 2010, 9, 2043-2054.
153. Fraga, M. F.; Ballestar, E.; Villar-Garea, A; Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG, Pérez-Rosado A, Calvo E, Lopez JA, Cano A, Calasanz MJ, Colomer D, Piris MA, Ahn N, Imhof A, Caldas C, Jenuwein T, Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 2005, 37, 391-400.
154. Elsheikh, S. E.; Green, A. R.; Rakha, E. A.; Powe, D. G.; Ahmed, R. A.; Collins, H. M.; Soria, D.; Garibaldi, J. M.; Paish, C. E.; Ammar, A. A.; Grainge, M. J.; Ball, G. R.; Abdelghany, M. K.; Martinez-Pomares, L.; Heery, D. M; Ellis, I. O. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 2009, 69, 3802-3809.
155. Ellinger, J.; Kahl, P.; Von der gathen, J.; Rogenhofer, S.; Heukamp, L. C.; Gütgemann, I.; Walter, B.; Hofstädter, F.; Büttner, R.; Müller, S. C.; Bastian, P. J.; von Ruecker A. Global levels of histone modifications predict prostate cancer recurrence. Prostate 2010, 70, 61-69.
156. Ellinger, J.; Kahl, P.; Von der gathen, J.; Heukamp, L. C.; Gütgemann, I.; Walter, B.; Hofstädter, F.; Bastian, P. J.; von Ruecker, A.; Müller, S. C.; Rogenhofer, S. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest. 2012, 30, 92-97.
157. Schneider, A. C.; Heukamp, L. C.; Rogenhofer, S.; Fechner, G.; Bastian, P. J.; von Ruecker, A.; Müller, S. C.; Ellinger, J. Global histone H4K20 trimethylation predicts cancer-specific survival in patients with muscle-invasive bladder cancer. BJU Int. 2011, 108 (8 Pt 2), E290-E296.
158. Seligson, D. B.; Horvath, S.; Mcbrian, M. A.; Mah, V.; Yu, H.; Tze, S.; Wang, Q.; Chia, D.; Goodglick, L.; Kurdistani, S. K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009, 174, 1619-1628.
159. Barlési, F.; Giaccone, G.; Gallegos-ruiz, M. I.; Loundou, A.; Span, S. W.; Lefesvre, P.; Kruyt, F. A.; Rodriguez, J. A. Global histone modifications predict prognosis of resected non small-cell lung cancer. J. Clin. Oncol. 2007, 25, 4358-4364.
160. Barbés, C.; Sánchez J.; Yebra, M. J.; Robert-Geró, M.; Hardisson, C. Effects of sinefungin and S-adenosylhomocysteine on DNA and protein methyltransferases from Streptomyces and other bacteria. FEMS Microbiol. Lett. 1990, 57, 239-243.
161. Greiner, D.; Bonaldi, T.; Eskeland, R.; Roemer, E.; Imhof, A. Identification of a specific inhibitor of the histon e me thy ltransferase SU(VAR)3-9. Nat. Chem. Biol. 2005, 1, 143-155.
162. Iwasa, E.; Hamashima, Y.; Fujishiro, S.; Higuchi, E.; Ito, A.; Yoshida, M.; Sodeoka, M. Total synthesis of (+)-chaetocin and its analogues: their histone methyltransferase G9a inhibitory activity. J. Am. Chem. Soc. 2010, 132, 4078-4089.
163. Lakshmikuttyamma, A.; Scott, S. A.; Decoteau, J. F.; Geyer, C. R. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 2010, 29, 576-88.
164. Sun, Y.; Takada, K.; Takemoto, Y.; Yoshida, M.; Nogi, Y.; Okada, S.; Matsunaga, S. Gliotoxin analogues from a marine-derived fungus, Penicillium sp., and their cytotoxic and histone methyltransferase inhibitory activities. J. Nat. Prod. 2012, 75, 111-124.
165. Kubicek, S.; O'sullivan, R. J.; August, E. M.; Hickey, E. R.; Zhang, Q.; Teodoro, M. L.; Rea, S.; Mechtler, K.; Kowalski, J. A.; Homon, C. A.; Kelly, T. A.; Jenuwein, T. Reversal of H3K9me2 by a small- molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 2007, 25, 473-481.
166. Vedadi, M.; Barsyte-lovejoy, D.; Liu, F.; Rival-Gervier, S.; Allali-Hassani, A.; Labrie, V.; Wigle, T. J.; Dimaggio, P. A.; Wasney, G. A.; Siarheyeva, A.; Dong, A.; Tempel, W.; Wang, S. C.; Chen, X.; Chau, I.; Mangano, T. J.; Huang, X. P.; Simpson, C. D.; Pattenden, S. G.; Norris, J. L.; Kireev, D. B.; Tripathy, A.; Edwards, A.; Roth, B. L.; Janzen, W. P.; Garcia, B. A.; Petronis, A.; Ellis, J.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Jin, J. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat. Chem. Biol. 2011, 7, 566-574.
167. Yuan, Y.; Wang, Q.; Paulk, J.; Kubicek, S.; Kemp, M. M.; Adams, D. J.; Shamji, A. F.; Wagner, B. K.; Schreiber, S. L. A small- molecule probe of the histone methyltransferase g9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem. Biol. 2012, 7, 1152-1157.
168. Bernt, K. M.; Armstrong, S. A. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am. Soc. Hematol. Educ. Program 2011, 2011, 354-360.
169. Yao, Y.; Chen, P.; Diao, J.; Cheng, G.; Deng, L.; Anglin, J. L.; Prasad, B. V.; Song, Y. Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies. J. Am. Chem. Soc. 2011, 133, 16746-16759.
170. Tan, J.; Yang, X.; Zhuang, L.; Jiang, X.; Chen, W.; Lee, P. L.; Karuturi, R. K.; Tan, P. B.; Liu, E. T.; Yu, Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21, 1050-1063.
171. rd.; Diaz, E.; LaFrance, L. V.; Mellinger, M.; Duquenne, C.; Tian, X.; Kruger, R. G.; McHugh, C. F.; Brandt, M.; Miller, W. H.; Dhanak, D.; Verma, S. K.; Tummino, P. J.; Creasy, C. L. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492, 108-112
172. Konze, K. D.; Ma, A.; Li, F.; Barsyte-Lovejoy, D.; Parton, T.; Macnevin, C. J.; Liu, F.; Gao, C.; Huang, X. P.; Kuznetsova, E.; Rougie, M.; Jiang, A.; Pattenden, S. G.; Norris, J. L.; James, L. I.; Roth, B. L.; Brown, P. J.; Frye, S. V.; Arrowsmith, C. H.; Hahn, K. M.; Wang, G. G.; Vedadi, M.; Jin, J. An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem. Biol. 2013 [Epub ahead of print].
173. Crea, F.; Fornaro, L.; Bocci, G.; Sun, L.; Farrar, W. L.; Falcone, A.; Danesi, R. EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev. 2012, 31 (3-4), 753-761.
174. Ferguson, A. D.; Larsen, N. A.; Howard, T.; Pollard, H.; Green, I.; Grande, C.; Cheung, T.; Garcia-Arenas, R.; Cowen, S.; Wu, J.; Godin, R.; Chen, H.; Keen, N. Structural basis of substrate methylation and inhibition of SMYD2. Structure 2011, 19, 1262-1273.
175. Lynch, J. T.; Harris, W. J.; Somervaille, T. C. LSD1 inhibition: a therapeutic strategy in cancer? Expert Opin. Ther. Targets 2012, [Epub ahead of print].
176. Edmondson, D. E.; Binda, C.; Mattevi, A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys. 2007, 464, 269-276.
177. Shi, Y.; Lan, F.; Matson, C.; Mulligan, P.; Whetstine, J. R.; Cole, P. A.; Casero, R. A.; Shi, Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119, 941-953.
178. Rotili, D.; Mai, A. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer 2011, 2, 663-679.
179. Schmidt, D. M.; Mccafferty, D. G. trans-2-Phenylcyclopro-pylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007, 46, 4408-4416.
180. Mimasu, S.; Umezawa, N.; Sato, S.; Higuchi, T.; Umehara, T.; Yokoyama, S. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1. Biochemistry 2010, 49, 6494-6503.
181. Metzger, E.; Wissmann, M.; Yin, N.; Müller, J. M; Schneider, R.; Peters, A. H., Günther, T.; Buettner, R; Schüle, R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437, 436-439
182. Willmann, D.; Lim, S.; Wetzel, S.; Metzger, E.; Jandausch, A.; Wilk, W.; Jung, M.; Forne, I.; Imhof, A.; Janzer, A.; Kirfel, J.; Waldmann, H.; Schüle, R.; Buettner, R. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int. J. Cancer. 2012, 131, 2704-2709.
183. Huang, Y.; Greene, E.; Murray Stewart, T.; Goodwin, A. C.; Baylin, S. B.; Woster PM, Casero RA Jr. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proc. Natl. Acad. Sci. USA 2007, 104, 8023-8028.
184. Huang, Y.; Marton, L. J.; Woster, P. M.; Casero, R. A. Polyamine analogues targeting epigenetic gene regulation. Essays Biochem. 2009, 46, 95-110.
185. Huang, Y.; Stewart, T. M.; Wu, Y.; Baylin, S. B., Marton, L. J.; Perkins, B.; Jones, R. J.; Woster, P. M.; Casero, R. A. Jr. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin. Cancer Res. 2009, 15, 7217-7228.
186. Wang, J.; Lu, F.; Ren, Q.; Sun, H.; Xu, Z.; Lan, R.; Liu, Y.; Ward, D.; Quan, J.; Ye, T.; Zhang, H. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res. 2011, 71, 7238-7249.
187. Hamada, S.; Suzuki, T.; Mino, K.; Koseki, K.; Oehme, F.; Flamme, I.; Ozasa, H.; Itoh, Y.; Ogasawara, D.; Komaarashi, H.; Kato, A.; Tsumoto, H.; Nakagawa, H.; Hasegawa, M.; Sasaki, R.; Mizukami, T.; Miyata, N. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. J. Med. Chem. 2010, 53, 5629-5638.
188. Kristensen, L. H.; Nielsen, A. L.; Helgstrand, C.; Lees, M.; Cloos, P.; Kastrup, J. S.; Helin, K.; Olsen, L; Gajhede, M. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor. FEBS J. 2012, 279, 1905-1914.
189. King, O. N.; Li, X. S.; Sakurai, M.; Kawamura, A.; Rose, N. R.; Ng, S. S.; Quinn, A. M.; Rai, G.; Mott, B. T.; Beswick, P.; Klose, R. J.; Oppermann, U.; Jadhav, A.; Heightman, T. D.; Maloney, D. J.; Schofield, C. J.; Simeonov, A. Quantitative high-throughput screening dentifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS ONE. 2010, 5, e15535.
190. Lohse, B.; Kristensen, J. L.; Kristensen, L. H.; Agger, K.; Helin, K.; Gajhede, M.; Clausen, R. P. Inhibitors of histone demethylases. Bioorg. Med. Chem. 2011, 19, 3625-3636.
191. Luo, X.; Liu, Y.; Kubicek, S.; Myllyharju, J.; Tumber, A.; Ng, S.; Che, K. H.; Podoll, J.; Heightman, T. D.; Oppermann, U.; Schreiber, S. L.; Wang, X. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J. Am. Chem. Soc. 2011, 133, 9451-9466.
192. Kruidenier, L.; Chung, C. W.; Cheng, Z.; Liddle, J.; Che, K.; Joberty, G.; Bantscheff, M.; Bountra, C.; Bridges, A.; Diallo, H.; Eberhard, D.; Hutchinson, S.; Jones, E.; Katso, R.; Leveridge, M.; Mander, P. K.; Mosley, J.; Ramirez-Molina, C.; Rowland, P.; Schofield, C. J.; Sheppard, R. J.; Smith, J. E.; Swales, C.; Tanner, R.; Thomas, P.; Tumber, A.; Drewes, G.; Oppermann, U.; Patel, D. J.; Lee, K.; Wilson, D. M. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012, 488, 404-418.
193. Mo, R.; Rao, S. M.; Zhu, Y. J. Identification of the MLL2 complex as a coactivator for estrogen receptor alpha. J. Biol. Chem. 2006, 281, 15714-15720.
194. Piao, G. H.; Piao, W. H.; He, Y.; Zhang, H. H.; Wang, G. Q.; Piao, Z. Hyper-methylation of RIZ1 tumor suppressor gene is involved in the early tumorigenesis of hepatocellular carcinoma. Histol. Histopathol. 2008, 23, 1171-1185.
195. Hasegawa, Y.; Matsubara, A.; Teishima, J.; Seki, M.; Mita, K.; Usui, T.; Oue, N.; Yasui, W. DNA methylation of the RIZ1 gene is associated with nuclear accumulation of p53 in prostate cancer. Cancer Sci. 2007, 98, 32-36.
196. Tam, W.; Gomez, M. F.; Chadburn, A.; Knowles, D. M.; Houldsworth, J. Lack of A563G (I188V) missense mutation in RIZ/ PRDM2 in human diffuse large B-cell lymphomas. Genes Chromosomes Cancer 2007, 46, 416-418.
197. Geli, J.; Nord, B.; Frisk, T.; Edström Elder, E.; Ekström, T. J.; Carling, T.; Bäckdahl, M.; Larsson, C. Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas. Int. J. Oncol. 2005, 26, 1385-1391.
198. Abbondanza, C.; De rosa, C.; D'Arcangelo, A.; Pacifico, M.; Spizuoco, C.; Piluso, G.; Di Zazzo, E.; Gazzerro, P.; Medici, N.; Moncharmont, B.; Puca, G. A. Identification of a functional estrogen-responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines. J. Cell Physiol. 2012, 227, 964-975.
199. Kim, J. Y.; Kim, K. B.; Eom, G. H.; Choe, N.; Kee, H. J.; Son, H. J.; Oh, S. T.; Kim, D. W.; Pak, J. H.; Baek, H. J.; Kook, H.; Hahn, Y.; Kook, H.; Chakravarti, D.; Seo, S. B. KDM3B Is the H3K9 Demethylase Involved in Transcriptional Activation of lmo2 in Leukemia. Mol. Cell Biol. 2012, 32, 2917-2933.
200. Björkman, M.; Ostling, P.; Härmä, V.; Virtanen, J.; Mpindi, J. P.; Rantala, J.; Mirtti, T.; Vesterinen, T.; Lundin, M.; Sankila, A.; Rannikko, A.; Kaivanto, E.; Kohonen, P.; Kallioniemi, O.; Nees, M. Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion. Oncogene 2012, 31, 3444-3456.
201. Taketani, T.; Taki, T.; Nakamura, H.; Taniwaki, M.; Masuda J.; Hayashi, Y. NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t (8;11)(p11; p15) and expression pattern of NSD family genes. Cancer Genet. Cytogenet. 2009, 190, 108-112.
202. Zhou, Z.; Thomsen, R.; Kahns, S.; Nielsen, A. L. The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells. Biochem. Biophys. Res. Commun. 2010, 398, 565-570.
203. Toyokawa, G.; Cho, H. S.; Masuda, K.; Yamane, Y.; Yoshimatsu, M.; Hayami, S.; Takawa, M.; Iwai, Y.; Daigo, Y.; Tsuchiya, E.; Tsunoda, T.; Field, H. I.; Kelly, J. D.; Neal, D. E.; Maehara, Y.; Ponder, B. A.; Nakamura, Y.; Hamamoto, R. Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. Neoplasia 2011, 13, 887-898.
204. Yew, C. W.; Lee, P.; Chan, W. K.; Lim, V. K.; Tay, S. K.; Tan, T. M.; Deng, L. W. A novel MLL5 isoform that is essential to activate E6 and E7 transcription in HPV16/18-associated cervical cancers. Cancer Res. 2011, 71, 6696-66707.
205. Deng, L. W.; Chiu, I.; Strominger, J. L. MLL 5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression. Proc. Natl. Acad. Sci USA 2004, 101, 757-762.
206. Li, H.; Rauch, T.; Chen, Z. X.; Szabó, P. E.; Riggs, A. D.; Pfeifer, G. P. The histone methyltransferase SETDB1 and the DNA methyl-transferase DNMT3A interact directly and localize to promoters silenced in cancer cells. J. Biol. Chem. 2006, 281, 19489-19500.
207. Yamada, D.; Kobayashi, S.; Yamamoto, H.; Tomimaru, Y.; Noda, T.; Uemura, M.; Wada, H.; Marubashi, S.; Eguchi, H.; Tanemura, M.; Doki, Y.; Mori, M.; Nagano, H. Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma: Clinical Impact on Recurrence after Hepatic Resection. Ann. Surg. Oncol. 2012, 19, 355-364.
208. Cho, H. S.; Toyokawa, G.; Daigo, Y.; Hayami S, Masuda K, Ikawa N, Yamane Y, Maejima K, Tsunoda T, Field HI, Kelly JD, Neal DE, Ponder BA, Maehara Y, Nakamura Y, Hamamoto R. The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. Int. J. Cancer 2012, 131, E179-E189.
209. Li, W.; Zhao, L.; Zang, W.; Liu, Z.; Chen, L.; Liu, T.; Xu, D.; Jia, J. Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. Biochem. Biophys. Res. Commun. 2011, 416, 372-378.
210. Toyokawa, G.; Cho, H. S.; Iwai, Y.; Yoshimatsu, M.; Takawa, M.; Hayami, S.; Maejima, K.; Shimizu, N.; Tanaka, H.; Tsunoda, T.; Field, H. I.; Kelly, J. D.; Neal, D. E.; Ponder, B. A.; Maehara, Y.; Nakamura, Y.; Hamamoto, R. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer. Prev. Res. (Phila) 2011, 4, 2051-2061.
211. Fukuda, T.; Tokunaga, A.; Sakamoto, R.; Yoshida, N. Fbxl10/Kdm2b deficiency accelerates neural progenitor cell death and leads to exencephaly. Mol. Cell Neurosci. 2011, 46, 14-24.
212. Matthieu, S. Structural Chemistry of Human SET Domain Protein Methyltransferases. Curr. Chem. Genomics 2011, 5, 85-94.
213. He, Y.; Korboukh, I.; Jin, J.; Huang, J. Targeting protein lysine methylation and demethylation in cancers. Acta. Biochim. Biophys. Sin. (Shanghai) 2012, 44, 70-79.
214. Dong, K. B.; Maksakova, I. A.; Mohn F.; Leung, D.; Appanah, R.; Lee, S.; Yang, H. W.; Lam, L. L.; Mager, D. L.; Schübeler, D.; Tachibana, M.; Shinkai, Y.; Lorincz, M. C. DNA methylation in ES cells requires the lysine methyltransferase G9a but not its catalytic activity. EMBO J. 2008, 27, 2691-2701.
215. Ikegami, K.; Iwatani, M.; Suzuki, M.; Tachibana, M.; Shinkai, Y.; Tanaka, S.; Greally, J. M.; Yagi, S.; Hattori, N.; Shiota, K. Genomewide and locus-specific DNA hypomethylation in G9a deficient mouse embryonic stem cells. Genes Cells 2007, 12, 1-11.
216. Damm, F.; Oberacker, T.; Thol, F.; Surdziel, E.; Wagner, K.; Chaturvedi, A.; Morgan, M.; Bomm, K.; Göhring, G.; Lübbert, M.; Kanz, L.; Fiedler, W.; Schlegelberger, B.; Heil, G.; Schlenk, R. F.; Döhner, K.; Döhner, H.; Krauter, J.; Ganser, A.; Heuser, M.; Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia. J. Clin. Oncol. 2011, 29, 682-689.
217. Cock-Rada, A. M.; Medjkane, S.; Janski, N.; Yousfi, N.; Perichon, M.; Chaussepied, M.; Chluba, J.; Langsley, G.; Weitzman, J. B. et al. SMYD3 promotes cancer invasion by epigenetic upregulation of the metalloproteinase MMP-9. Cancer Res. 2012, 72, 810-20.
218. Ferrari-Amorotti, G.; Fragliasso, V.; Esteki, R.; Prudente, Z.; Soliera, A. R.; Cattelani, S.; Manzotti, G.; Grisendi, G.; Dominici, M.; Pieraccioli, M.; Raschellà, G.; Chiodoni, C.; Colombo, M. P.; Calabretta, B. Inhibiting interactions of lysine demethylase LSD1 with Snail/Slug blocks cancer cell invasion. Cancer Res. 2013, 73, 235-245.
219. Zeng, J.; Ge, Z.; Wang, L.; Li, Q.; Wang, N.; Björkholm, M.; Jia, J.; Xu, D. The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells. Gastroenterology 2010,138, 981-992
220. Hidalgo, A.; Baudis, M.; Petersen, I.; Arreola, H.; Piña, P.; Vázquez-Ortiz, G.; Hernández, D.; González, J.; Lazos, M.; López, R.; Pérez, C.; García, J.; Vázquez, K.; Alatorre, B.; Salcedo, M. Microarray comparative genomic hybridization detection of chromosomal imbalances in uterine cervix carcinoma. BMC Cancer 2005, 5, 77.
221. van Zutven, L. J.; Onen, E.; Velthuizen, S. C. et al. Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer 2006, 45, 437-446.
222. Kawazu, M.; Saso, K.; Tong, K. I.; McQuire, T.; Goto, K.; Son, D. O.; Wakeham, A.; Miyagishi, M.; Mak, T. W.; Okada, H. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One 2011, 6, e17830.
223. Nijwening, J. H.; Geutjes, E. J.; Bernards, R.; Beijersbergen, R. L. The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence. PLoS One 2011, 6, e25235.
224. De Santa, F.; Narang, V.; Yap, Z. H.; Tusi, B. K.; Burgold, T.; Austenaa, L.; Bucci, G.; Caganova, M.; Notarbartolo, S.; Casola, S.; Testa, G.; Sung, W. K.; Wei, C. L.; Natoli, G. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 2009, 28, 3341-3352.